ABSTRACT
Obesity is characterized by a blunted lipolytic response in abdominal subcutaneous adipose tissue (SAT) and low circulating vitamin D levels. Here we investigated whether an impaired SAT lipolytic response coincides with an impaired SAT vitamin D release in eight lean and six obese men. 25-hydroxyvitamin D3 [25(OH)D3 ] and 1,25-dihydroxyvitamin D3 [1,25(OH)2 D3 ] fluxes across SAT were measured using arterio-venous blood sampling in combination with AT blood flow measurements after an overnight fast and during 1-hr intravenous infusion of the non-selective ß-adrenergic agonist isoprenaline (20 ng·kg FFM-1 ·min-1 ). 1,25(OH)2 D3 was released across abdominal SAT during isoprenaline infusion in lean [-0.01 (-0.04 to 0.00) pmol*100 g tissue-1 *min-1 , p = .017 vs. zero flux], but not in obese men [0.01 (0.00 to 0.02) pmol*100 g tissue-1 *min-1 , p = .116 vs. zero flux], and accompanied by an impaired isoprenaline-induced lipolytic response in abdominal SAT of obese versus lean men. Isoprenaline had no significant effects on net 25(OH)D3 release across abdominal SAT and plasma vitamin D metabolites in lean and obese men. To conclude, a blunted isoprenaline-mediated lipolysis is accompanied by reduced release of 1,25(OH)2 D3 vitamin D across abdominal SAT in obesity.
Subject(s)
Abdominal Fat/metabolism , Adrenergic beta-Agonists/pharmacology , Dihydroxycholecalciferols/metabolism , Isoproterenol/pharmacology , Obesity/metabolism , Abdominal Fat/drug effects , Adrenergic beta-Agonists/administration & dosage , Adult , Dihydroxycholecalciferols/blood , Humans , Infusions, Intravenous , Isoproterenol/administration & dosage , Lipolysis , Male , Middle AgedABSTRACT
Vitamin D has immunomodulatory, anti-inflammatory, antioxidant, and anti-fibrotic actions that may impact on the occurrence and outcome of immune-mediated disease. The goals of this review are to describe the nature of these expanded roles, examine the implications of vitamin D deficiency in autoimmune hepatitis, and identify opportunities for future investigation. Abstracts were identified in PubMed by multiple search terms. Full-length articles were selected for review, and secondary and tertiary bibliographies were developed. Vitamin D receptors are expressed on the principal cell populations involved in the innate and adaptive immune responses. Macrophages and dendritic cells can produce 1,25-dihydroxyvitamin D within the microenvironment. This active form of vitamin D can inhibit immune cell proliferation, promote an anti-inflammatory cytokine profile, expand regulatory T cells, enhance glucocorticoid actions, increase glutathione production, and inhibit hepatic stellate cells. Vitamin D deficiency has been commonly present in patients with immune-mediated liver and non-liver diseases, and it has been associated with histological severity, advanced hepatic fibrosis, and non-response to conventional glucocorticoid therapy in autoimmune hepatitis. Vitamin D analogues with high potency, low calcemic effects, and independence from hepatic hydroxylation are possible interventions. In conclusion, vitamin D has properties that could ameliorate immune-mediated disease, and vitamin D deficiency has been a common finding in immune-mediated liver and non-liver diseases, including autoimmune hepatitis. Loss of vitamin D-dependent homeostatic mechanisms may promote disease progression. Vitamin D analogues that are independent of hepatic hydroxylation constitute an investigational opportunity to supplement current management of autoimmune hepatitis.
Subject(s)
Hepatitis, Autoimmune/immunology , Vitamin D Deficiency/immunology , Vitamin D/immunology , Adaptive Immunity/immunology , Autoimmune Diseases/immunology , Autoimmune Diseases/metabolism , Autoimmunity/immunology , Cytokines , Dendritic Cells/immunology , Dihydroxycholecalciferols/metabolism , Fibrosis , Glucocorticoids/metabolism , Glutathione/metabolism , Hepatic Stellate Cells/metabolism , Hepatitis, Autoimmune/metabolism , Humans , Immunity, Innate/immunology , Inflammation , Liver Cirrhosis/immunology , Liver Cirrhosis/metabolism , Macrophages/immunology , T-Lymphocytes , Vitamin D/metabolism , Vitamin D Deficiency/metabolismABSTRACT
We evaluated associations of serum 25-hydroxyvitamin D (25[OH]D) and 1,25-dihydroxyvitamin D (1,25[OH]2D) levels in a cohort of HIV-infected and HIV-uninfected men at risk for infection in the United States. Stored samples collected between 1999 and 2008 were tested for vitamin D metabolites between 2014 and 2015. Vitamin D deficiency was defined as a serum concentration of 25[OH]D <20 ng/ml. Multivariate models were used to assess associations of various demographic and clinical factors with vitamin D status. HIV-infected men on effective antiretroviral therapy (n = 640) and HIV-uninfected men (n = 99) had comparable levels of 25[OH]D and 1,25[OH]2D, and prevalences of vitamin D deficiency were 41% in HIV-infected and 44% in HIV-uninfected men, respectively. Self-reported black or other non-white race, obesity, and normal kidney function were significant predictors of vitamin D deficiency regardless of HIV serostatus. Lower CD4+ T cell count was associated with vitamin D deficiency in HIV-infected men, while current ritonavir use was protective. Self-reported black race was the only factor significantly associated with higher levels of 1,25[OH]2D (vs. whites; ß = 4.85 pg/ml, p = .003). Levels of 1,25[OH]2D and 25[OH]D were positively correlated in HIV-infected men (ß = 0.32 pg/ml, p < .001), but not in uninfected men (ß = -0.09 pg/ml, p = .623; p < .05 for interaction). Vitamin D deficiency was prevalent regardless of HIV serostatus in this cohort, suggesting that HIV infection did not confer additional risk of deficiency in this cohort of well-treated HIV-infected men. However, HIV infection and race may have implications for vitamin D metabolism and 1,25[OH]2D levels.
Subject(s)
HIV Infections/complications , Vitamin D Deficiency/complications , Vitamin D Deficiency/epidemiology , Aged , Anti-HIV Agents/therapeutic use , Dihydroxycholecalciferols/blood , Dihydroxycholecalciferols/metabolism , HIV Infections/drug therapy , Humans , Male , Middle Aged , Prevalence , Prospective Studies , Risk Factors , United States , Vitamin D/analogs & derivatives , Vitamin D/blood , Vitamin D/metabolismABSTRACT
The vitamin D3 metabolite, 20S,23S-dihydroxyvitamin D3, was chemically synthesized for the first time and identified to be the same as the enzymatically produced metabolite. The C23 absolute configurations of both 20S,23S/R-dihydroxyvitamin D3 epimers were unambiguously assigned by NMR and Mosher ester analysis. Their kinetics of CYP27B1 metabolism were investigated during the production of their 1α-hydroxylated derivatives. Bioactivities of these products were compared in terms of vitamin D3 receptor activation, anti-inflammatory, and antiproliferative activities.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/chemistry , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Antineoplastic Agents/pharmacology , Cholecalciferol/metabolism , Dihydroxycholecalciferols/pharmacology , Receptors, Immunologic/antagonists & inhibitors , Anti-Inflammatory Agents, Non-Steroidal/metabolism , Antineoplastic Agents/chemistry , Antineoplastic Agents/metabolism , Cell Proliferation/drug effects , Cholecalciferol/analogs & derivatives , Cholecalciferol/chemistry , Dihydroxycholecalciferols/chemistry , Dihydroxycholecalciferols/metabolism , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Humans , Models, Molecular , Molecular Structure , Receptors, Immunologic/immunology , Stereoisomerism , Structure-Activity Relationship , Tumor Cells, CulturedABSTRACT
Klotho, a protein mainly expressed in kidney and cerebral choroid plexus, is a powerful regulator of 1,25(OH)2D3 formation. Klotho-deficient mice (kl/kl) suffer from excessive plasma 1,25(OH)2D3-, Ca(2+)- and phosphate-concentrations, leading to severe soft tissue calcification and accelerated aging. NH4Cl treatment prevents tissue calcification and premature ageing without affecting 1,25(OH)2D3-formation. The present study explored the impact of excessive 1,25(OH)2D3 formation in NH4Cl-treated kl/kl-mice on behavior. To this end kl/kl-mice and wild-type mice were treated with NH4Cl and either control diet or vitamin D deficient diet (LVD). As a result, plasma 1,25(OH)2D3-, Ca(2+)- and phosphate-concentrations were significantly higher in untreated and in NH4Cl-treated kl/kl-mice than in wild-type mice, a difference abrogated by LVD. In each, open field, dark-light box, and O-maze NH4Cl-treated kl/kl-mice showed significantly higher exploratory behavior than untreated wild-type mice, a difference abrogated by LVD. The time of floating in the forced swimming test was significantly shorter in NH4Cl treated kl/kl-mice compared to untreated wild-type mice and to kl/kl-mice on LVD. In wild-type animals, NH4Cl treatment did not significantly alter 1,25(OH)2D3, calcium and phosphate concentrations or exploratory behavior. In conclusion, the excessive 1,25(OH)2D3 formation in klotho-hypomorphic mice has a profound effect on murine behavior.
Subject(s)
Dihydroxycholecalciferols/metabolism , Exploratory Behavior , Glucuronidase/deficiency , Ammonium Chloride/administration & dosage , Animals , Calcium/blood , Dihydroxycholecalciferols/blood , Hyperkinesis , Klotho Proteins , Mice , Phosphates/blood , Psychomotor AgitationABSTRACT
CYP11A1 hydroxylates vitamin D3 producing 20S-hydroxyvitamin D3 [20(OH)D3] and 20S,23-dihydroxyvitamin D3 [20,23(OH)2D3] as the major and most characterized metabolites. Both display immuno-regulatory and anti-cancer properties while being non-calcemic. A previous study indicated 20(OH)D3 can be metabolized by rat CYP24A1 to products including 20S,24-dihydroxyvitamin D3 [20,24(OH)2D3] and 20S,25-dihydroxyvitamin D3, with both producing greater inhibition of melanoma colony formation than 20(OH)D3. The aim of this study was to characterize the ability of rat and human CYP24A1 to metabolize 20(OH)D3 and 20,23(OH)2D3. Both isoforms metabolized 20(OH)D3 to the same dihydroxyvitamin D species with no secondary metabolites being observed. Hydroxylation at C24 produced both enantiomers of 20,24(OH)2D3. For rat CYP24A1 the preferred initial site of hydroxylation was at C24 whereas the human enzyme preferred C25. 20,23(OH)2D3 was initially metabolized to 20S,23,24-trihydroxyvitamin D3 and 20S,23,25-trihydroxyvitamin D3 by rat and human CYP24A1 as determined by NMR, with both isoforms showing a preference for initial hydroxylation at C25. CYP24A1 was able to further oxidize these metabolites in a series of reactions which included the cleavage of C23-C24 bond, as indicated by high resolution mass spectrometry of the products, analogous to the catabolism of 1,25(OH)2D3 via the C24-oxidation pathway. Similar catalytic efficiencies were observed for the metabolism of 20(OH)D3 and 20,23(OH)2D3 by human CYP24A1 and were lower than for the metabolism of 1,25(OH)2D3. We conclude that rat and human CYP24A1 metabolizes 20(OH)D3 producing only dihydroxyvitamin D3 species as products which retain biological activity, whereas 20,23(OH)2D3 undergoes multiple oxidations which include cleavage of the side chain.
Subject(s)
Calcifediol/analogs & derivatives , Dihydroxycholecalciferols/metabolism , Vitamin D3 24-Hydroxylase/metabolism , Animals , Calcifediol/metabolism , Humans , Hydroxylation , Oxidation-Reduction , Rats , Vitamin D/analogs & derivatives , Vitamin D/metabolismABSTRACT
RORα and RORγ are expressed in human skin cells that produce the noncalcemic 20-hydroxyvitamin D3 [20(OH)D3] and 20,23-dihydroxyvitamin D3 [20,23(OH)2D3]. Chinese hamster ovary (CHO) cells stably expressing a Tet-on RORα or RORγ expression vector and a ROR-responsive element (RORE)-LUC reporter, and a mammalian 2-hybrid model examining the interaction between the ligand binding domain (LBD) of RORα or RORγ with an LBD-interacting LXXLL-peptide, were used to study ROR-antagonist activities. These assays revealed that 20(OH)D3 and 20,23(OH)2D3 function as antagonists of RORα and RORγ. Moreover, 20(OH)D3 inhibited the activation of the promoter of the Bmal1 and G6pase genes, targets of RORα, and 20(OH)D3 and 20,23(OH)2D3 inhibited Il17 promoter activity in Jurkat cells overexpressing RORα or RORγ. Molecular modeling using crystal structures of the LBDs of RORα and RORγ revealed docking scores for 20(OH)D3, 20,23(OH)2D3 and 1,25(OH)2D3 similar to those of the natural ligands, predicting good binding to the receptor. Notably, 20(OH)D3, 20,23(OH)2D3, and 1,25(OH)2D3 inhibited RORE-mediated activation of a reporter in keratinocytes and melanoma cells and inhibited IL-17 production by immune cells. Our study identifies a novel signaling pathway, in which 20(OH)D3 and 20,23(OH)2D3 act as antagonists or inverse agonists of RORα and RORγ, that opens new possibilities for local (skin) or systemic regulation.-Slominski, A. T., Kim, T.-K., Takeda, Y., Janjetovic, Z., BrozËyna, A. A., Skobowiat, C., Wang, J., Postlethwaite, A., Li, W., Tuckey, R. C., Jetten, A. M. RORα and ROR γ are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D.
Subject(s)
Calcifediol/analogs & derivatives , Dihydroxycholecalciferols/metabolism , Nuclear Receptor Subfamily 1, Group F, Member 1/genetics , Nuclear Receptor Subfamily 1, Group F, Member 1/metabolism , Nuclear Receptor Subfamily 1, Group F, Member 3/genetics , Nuclear Receptor Subfamily 1, Group F, Member 3/metabolism , Skin/metabolism , ARNTL Transcription Factors/genetics , ARNTL Transcription Factors/metabolism , Animals , CHO Cells , Calcifediol/metabolism , Cell Line, Tumor , Cells, Cultured , Cricetulus , Female , Glucose-6-Phosphatase/antagonists & inhibitors , Glucose-6-Phosphatase/genetics , Humans , Interleukin-17/genetics , Interleukin-17/metabolism , Jurkat Cells , Keratinocytes/metabolism , Melanoma/genetics , Melanoma/metabolism , Mice , Mice, Inbred DBA , Promoter Regions, Genetic/geneticsABSTRACT
RATIONALE: Chronic stress or hypercortisolism may increase the risks of depression, cardiac disorders, and osteoporosis, which are also associated with vitamin D (VD) deficiency. Both glucocorticoid receptor (GR) and vitamin D receptor (VDR) are widely distributed and affect many aspects of human physiology. The cross talk between the two steroids is pervasive, but the effect of glucocorticoids on circulating VD and local VD metabolism remains elusive. OBJECTIVES: To fill this critical gap, we assessed the alterations of circulating VD and VD intracrine system in the brain and myocardium of rats treated with two different doses (0.2 and 2 mg/kg/day, respectively) of dexamethasone (Dex). RESULTS: Daily treatment with 2 mg/kg of Dex for 10 days induced the rats to a depressive-like state and decreased the expression of both VDR and the cytochromes P450 enzymes involved in VD activation (CYP27B1) and catabolism (CYP24A1) in the prefrontal cortex and hippocampus. Meanwhile, the dose of 0.2 mg/kg Dex increased the expression of VDR in the prefrontal cortex but inhibited CYP27B1/CYP24A1/VDR expression in the hippocampus. Similarly, in the myocardium, the rats treated with Dex showed significantly lower expression of CYP27B1/CYP24A1/VDR. Renal VD metabolism and serum VD status were unchanged in 0.2 mg/kg Dex-treated rats. However, the higher dose suppressed the three key players involved in VD metabolism but did not alter serum VD levels. CONCLUSION: These data provide new evidence that glucocorticoids could affect intracrine actions of VD in the brain and myocardium, which suggests the potential involvement of VD in the neural and cardiac dysfunctions induced by glucocorticoid excess.
Subject(s)
Brain Chemistry/drug effects , Dexamethasone/pharmacology , Heart/drug effects , Myocardium/metabolism , Vitamin D/metabolism , Vitamins/metabolism , 25-Hydroxyvitamin D3 1-alpha-Hydroxylase/biosynthesis , Anhedonia/drug effects , Animals , Behavior, Animal/drug effects , Body Weight/drug effects , Dihydroxycholecalciferols/metabolism , Hydroxycholecalciferols/metabolism , Kidney/drug effects , Kidney/metabolism , Male , Rats , Rats, Sprague-Dawley , Swimming/psychology , Vitamin D3 24-Hydroxylase/biosynthesisABSTRACT
Constitutive androstane receptor (CAR) was originally identified as xenobiotic sensor that regulates the expression of cytochrome P450 genes. However, recent studies suggest that this nuclear receptor is also involved in the regulation of energy metabolism including glucose and lipid homeostasis. This study investigated the role of CAR in the regulation of bone mass in vivo using CAR(-/-) mice. Endogenous mRNA expression of CAR was observed in both primary osteoblasts and osteoclast precursors. CAR(-/-) mice have exhibited significant increase in whole body bone mineral density (BMD) by 9.5% (P < 0.01) and 5.5% (P < 0.05) at 10 and 15 weeks of age, respectively, compared with WT mice in males. Microcomputed tomography analysis of proximal tibia demonstrated a significant increase in trabecular bone volume (62.7%), trabecular number (54.1%) in male CAR(-/-) mice compared with WT mice. However, primary culture of calvarial cells exhibited no significant changes in osteogenic differentiation potential between CAR(-/-) and WT. In addition, the number of tartrate-resistant acid-phosphatase positive osteoclasts in the femur and serum level of CTx was not different between CAR(-/-) and WT mice. The higher BMD and microstructural parameters were not observed in female mice. Interestingly, serum level of testosterone in male CAR(-/-) mice was 2.5-fold higher compared with WT mice and the mRNA expressions of Cyp2b9 and 2b10 in the liver, which regulate testosterone metabolism, were significantly down-regulated in male CAR(-/-) mice. Furthermore, the difference in BMD between CAR(-/-) and WT mice disappeared at 8 weeks after performing orchiectomy. CAR(-/-) mice also exhibited significant increase in serum 1,25(OH)2 D3 levels but Cyp 27B1 which converts 25(OH)D3 to 1,25(OH)2 D3 was significantly down-regulated compared to WT mice. These results suggest that in vivo deletion of CAR resulted in higher bone mass, which appears to be a result from reduced metabolism of testosterone due to down-regulation of Cyp2b.
Subject(s)
Bone Density/physiology , Receptors, Cytoplasmic and Nuclear/metabolism , Alkaline Phosphatase/metabolism , Animals , Aryl Hydrocarbon Hydroxylases/genetics , Aryl Hydrocarbon Hydroxylases/metabolism , Bone Density/genetics , Cells, Cultured , Constitutive Androstane Receptor , Dihydroxycholecalciferols/metabolism , Female , Gene Expression Regulation/physiology , Macrophages/physiology , Male , Mice , Mice, Knockout , Orchiectomy , Receptors, Cytoplasmic and Nuclear/genetics , Testosterone/metabolismABSTRACT
Cytochrome P450scc (CYP11A1) can hydroxylate vitamin D(3), producing 20S-hydroxyvitamin D(3) [20(OH)D(3)] and 20S,23-dihydroxyvitamin D(3) [20,23(OH)(2)D(3)] as the major metabolites. These are biologically active, acting as partial vitamin D receptor (VDR) agonists. Minor products include 17-hydroxyvitamin D(3), 17,20-dihydroxyvitamin D(3), and 17,20,23-trihydroxyvitamin D(3). In the current study, we have further analyzed the reaction products from cytochrome P450scc (P450scc) action on vitamin D(3) and have identified two 22-hydroxy derivatives as products, 22-hydroxyvitamin D(3) [22(OH)D(3)] and 20S,22-dihydroxyvitamin D(3) [20,22(OH)(2)D(3)]. The structures of both of these derivatives were determined by NMR. P450scc could convert purified 22(OH)D(3) to 20,22(OH)(2)D(3). The 20,22(OH)(2)D(3) could also be produced from 20(OH)D(3) and was metabolized to a trihydroxyvitamin D(3) product. We compared the biological activities of these new derivatives with those of 20(OH)D(3), 20,23(OH)(2)D(3), and 1α,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)]. 1,25(OH)(2)D(3), 20(OH)D(3), 22(OH)D(3), 20,23(OH)(2)D(3), and 20,22(OH)(2)D(3) significantly inhibited keratinocyte proliferation in a dose-dependent manner. The strongest inducers of involucrin expression (a marker of keratinocyte differentiation) were 20,23(OH)(2)D(3), 20,22(OH)(2)D(3), 20(OH)D(3), and 1,25(OH)(2)D(3), with 22(OH)D(3) having a heterogeneous effect. Little or no stimulation of CYP24 mRNA expression was observed for all the analogs tested except for 1,25(OH)(2)D(3). All the compounds stimulated VDR translocation from the cytoplasm to the nucleus with 22(OH)D(3) and 20,22(OH)(2)D(3) having less effect than 1,25(OH)(2)D(3) and 20(OH)D(3). Thus, we have identified 22(OH)D(3) and 20,22(OH)(2)D(3) as products of CYP11A1 action on vitamin D(3) and shown that, like 20(OH)D(3) and 20,23(OH)(2)D(3), they are active on keratinocytes via the VDR, however, showing a degree of phenotypic heterogeneity in comparison with other P450scc-derived hydroxy metabolites of vitamin D(3).
Subject(s)
Calcifediol/analogs & derivatives , Cholecalciferol/metabolism , Cholesterol Side-Chain Cleavage Enzyme/metabolism , Hydroxycholecalciferols/chemistry , Hydroxycholecalciferols/metabolism , Skin/metabolism , 25-Hydroxyvitamin D3 1-alpha-Hydroxylase/metabolism , Calcifediol/chemistry , Calcifediol/metabolism , Cell Proliferation/drug effects , Cells, Cultured , Cholecalciferol/chemistry , Dihydroxycholecalciferols/chemistry , Dihydroxycholecalciferols/metabolism , Humans , Keratinocytes/drug effects , Keratinocytes/metabolism , Magnetic Resonance Spectroscopy/methods , Protein Precursors/genetics , Protein Precursors/metabolism , Protein Transport/drug effects , Receptors, Calcitriol/genetics , Receptors, Calcitriol/metabolism , Skin/cytology , Steroid Hydroxylases/genetics , Steroid Hydroxylases/metabolism , Vitamin D3 24-HydroxylaseABSTRACT
We have examined effects of the 20,23-dihydroxyvitamin D3 (20,23(OH)2D3), on differentiation and proliferation of human keratinocytes and the anti-inflammatory potential of 20,23(OH)2D3 from its action on nuclear factor-kappaB (NF-kappaB). 20,23(OH)2D3 inhibited growth of keratinocytes with a potency comparable to that for 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). Cell cycle analysis showed that this inhibition was associated with G1/G0 and G2/M arrests. 20,23(OH)2D3 stimulated production of involucrin mRNA and inhibited production of cytokeratin 14 mRNA in a manner similar to that seen for 1,25(OH)2D3. Flow cytometry showed that these effects were accompanied by increased involucrin protein expression, and an increase in the cell size and granularity. Silencing of the vitamin D receptor (VDR) by corresponding siRNA abolished the stimulatory effect on involucrin gene expression demonstrating an involvement of VDR in 20,23(OH)2D3 action. This mode of action was further substantiated by stimulation of CYP24 gene expression and stimulation of the CYP24 promoter-driven reporter gene activity. 20,23(OH)2D3 displayed several fold lower potency for induction of CYP24 gene expression than 1,25(OH)2D3. Finally, 20,23(OH)2D3 inhibited the transcriptional activity of NF-kappaB in keratinocytes as demonstrated by EMSA, NF-kappaB-driven reporter gene activity assays and measurements of translocation of p65 from the cytoplasm to the nucleus. These inhibitory effects were connected with stimulation of the expression of IkappaBalpha with subsequent sequestration of NF-kappaB in the cytoplasm and consequent attenuation of transcriptional activity. In summary, we have characterized 20,23(OH)2D3 as a novel secosteroidal regulator of keratinocytes proliferation and differentiation and a modifier of their immune activity.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Calcitriol/pharmacology , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Cholesterol Side-Chain Cleavage Enzyme/metabolism , Dihydroxycholecalciferols/pharmacology , Keratinocytes/drug effects , NF-kappa B/metabolism , 25-Hydroxyvitamin D3 1-alpha-Hydroxylase/metabolism , Anti-Inflammatory Agents/metabolism , Biotransformation , Calcitriol/metabolism , Cell Cycle/drug effects , Cells, Cultured , Cholestanetriol 26-Monooxygenase/metabolism , Dihydroxycholecalciferols/metabolism , Dose-Response Relationship, Drug , Enzyme Induction , Humans , I-kappa B Proteins/metabolism , Keratin-14/genetics , Keratinocytes/enzymology , NF-KappaB Inhibitor alpha , NF-kappa B/genetics , Promoter Regions, Genetic , Protein Precursors/genetics , RNA Interference , RNA, Messenger/metabolism , Receptors, Calcitriol/genetics , Receptors, Calcitriol/metabolism , Steroid Hydroxylases/biosynthesis , Time Factors , Transcription Factor RelA/metabolism , Transcription, Genetic , Transfection , Vitamin D3 24-HydroxylaseABSTRACT
We have shown that activin A, a cytokine implicated in regulating B-cell proliferation, is severely deficient in alveolar macrophages from patients with pulmonary alveolar proteinosis (PAP), an autoimmune disorder characterized by surfactant accumulation and neutralizing autoantibodies to granulocyte-macrophage colony stimulating factor. Mechanisms of activin regulation in alveolar macrophages are not well understood. Based on previous gene array results from PAP bronchoalveolar lavage cells suggesting deficiencies in vitamin D target genes, and on recent evidence of vitamin D receptor elements (VDREs) in the human activin A gene promoter, we investigated the effects of 1,25-dihydroxyvitamin D (vitamin D(3)) on activin A expression in alveolar macrophages from healthy individuals and PAP patients. Activin A expression was stimulated by LPS in cultures of either healthy control or PAP alveolar macrophages; in contrast, vitamin D(3) increased activin A only in healthy controls but not in PAP. Compared to healthy controls, freshly obtained (uncultured) PAP alveolar macrophages displayed healthy intrinsic vitamin D receptor expression but deficient expression of vitamin D target genes, cathelicidin and thioredoxin interacting protein. PAP patients also demonstrated a relative insufficiency of circulating vitamin D. Investigation of activin A in murine alveolar macrophages confirmed a lack of functional response to vitamin D as anticipated since murine activin A does not contain VDREs. Results suggest that mechanisms of activin A deficiency in PAP alveolar macrophages may involve dysregulation of a novel species-specific vitamin D-activin A pathway.
Subject(s)
Activins/metabolism , Dihydroxycholecalciferols/metabolism , Gene Expression Regulation , Macrophages, Alveolar/pathology , Pulmonary Alveolar Proteinosis/immunology , Pulmonary Alveolar Proteinosis/physiopathology , Activins/genetics , Adult , Animals , Autoantibodies/biosynthesis , Autoimmune Diseases/immunology , Autoimmune Diseases/physiopathology , B-Lymphocytes , Cells, Cultured , Dihydroxycholecalciferols/genetics , Dihydroxycholecalciferols/pharmacology , Female , Humans , Lymphocyte Activation , Macrophages, Alveolar/immunology , Macrophages, Alveolar/metabolism , Male , Mice , Mice, Inbred C57BLABSTRACT
This study investigated the effect of intense physical activities that generate high mechanical constraints on bone metabolism and serum leptin concentrations and the potential relationships among bone mineral density (BMD), bone biochemical markers and leptin variation. Thirteen male decathletes (mean age 22.4 +/- 2.9 years), nationally or internationally ranked (15.5 h/week of training), were compared with 13 healthy sedentary subjects (mean age 25.9 +/- 3.3 years). BMD was measured by DEXA and bone turnover was evaluated by specific markers. Leptin and calciotropic hormones levels were analysed in parallel. BMDs were higher in athletes than in controls at total body (13.9%), lumbar spine (17%), femoral neck (25%) and radius (9%), but not at the head. Athletes presented higher concentrations of osteocalcin (59.8%), cross-linked C-telopeptide of type-I collagen (41.1%) and 1,25-dihydroxyvitamin-D (37.1%). Basal leptin concentration was lower in athletes (0.94 +/- 0.54 vs. 5.07 +/- 1.1 ng ml(-1)), and this difference persisted when leptin levels were adjusted for whole body fat mass (WBFM). No difference was observed for bone-specific alkaline phosphatase or intact parathyroid hormone. Serum leptin levels were negatively correlated with various BMD values only when both the groups were pooled (n = 26). This relationship did not persist when leptin levels were adjusted for WBFM. Male athletes, who practise sports generating high mechanical constraints on the body, present a specific bone metabolism that includes high BMD, as well as high bone turnover. The blunted leptin secretion did not seem to have deleterious effect on the process of bone adaptation to high mechanical constraints.
Subject(s)
Bone and Bones/metabolism , Leptin/deficiency , Sports , Adult , Alkaline Phosphatase/analysis , Alkaline Phosphatase/metabolism , Biomarkers , Body Composition , Bone Density/physiology , Bone Remodeling/physiology , Collagen Type I/analysis , Collagen Type I/metabolism , Dihydroxycholecalciferols/analysis , Dihydroxycholecalciferols/metabolism , Exercise/physiology , Femur/metabolism , Humans , Lumbar Vertebrae/metabolism , Male , Osteocalcin/analysis , Osteocalcin/metabolism , Parathyroid Hormone/blood , Parathyroid Hormone/metabolismABSTRACT
OBJECTIVE: This study aimed to show that during hypokinesia (HK) electrolyte imbalance increases more in trained than untrained subjects and that electrolyte loss increases more with higher than lower electrolyte imbalance in trained than untrained subjects. METHODS: Studies were conducted during 364-day HK. Subjects were equally divided in four groups: trained ambulatory control subjects (TACS), trained hypokinetic subjects (THKS), untrained ambulatory control subjects (UACS) and untrained hypokinetic subjects (UHKS). THKS and UHKS were limited to average walking distances of 0.5+/-0.1 km day(-1). TACS were running average distances of 9.8+/-1.3 and UACS were walking average distances of 1.8+/-0.2 km day(-1). RESULTS: Plasma potassium (K(+)), calcium (Ca(+2)) and magnesium (Mg(+2)) levels, urine and fecal electrolyte excretion, electrolyte imbalance, plasma aldosterone (PA) and plasma rennin activity (PRA) increased significantly (p<0.05), while electrolyte absorption, plasma intact parathyroid hormone (iPTH) and dihydroxyvitamin D (1,25 (OH)(2) D(3)) levels decreased significantly (p<0.05) in THKS and UHKS compared with their pre-HK values and their respective controls (TACS and UACS). Electrolyte imbalance, plasma electrolyte levels, urine and fecal electrolyte excretion, PA and PRA levels increased more significantly (p<0.05), while electrolyte absorption, plasma iPTH and 1, 25 (OH)(2) D(3) levels decreased more significantly (p<0.05) in THKS than in UHKS. CONCLUSION: The higher electrolyte imbalance in trained as compared to untrained subjects shows that the risk of higher electrolyte imbalance is inversely related to the magnitude of physical conditioning. The higher electrolyte loss with higher than lower electrolyte imbalance shows that the risk of higher electrolyte loss is inversely related to the magnitude of electrolyte imbalance. In conclusion electrolyte imbalance increases more in trained than untrained subjects and that electrolyte loss increase more with higher than lower electrolyte imbalance indicating that during prolonged HK the use of electrolytes decreases more with higher than lower physical conditioning.
Subject(s)
Exercise/physiology , Hypokinesia/blood , Hypokinesia/urine , Water-Electrolyte Balance , Adult , Calcium/blood , Calcium/metabolism , Calcium/urine , Dihydroxycholecalciferols/blood , Dihydroxycholecalciferols/metabolism , Dihydroxycholecalciferols/urine , Feces/chemistry , Humans , Hypokinesia/physiopathology , Magnesium/blood , Magnesium/metabolism , Magnesium/urine , Male , Parathyroid Hormone/blood , Parathyroid Hormone/metabolism , Potassium/blood , Potassium/metabolism , Potassium/urine , Running , Time Factors , Walking , Water-Electrolyte ImbalanceABSTRACT
Our previous microarray analysis showed that N-methyl-N-nitrosourea (MNU) transformed MCF12F breast epithelial cells exhibited upregulation of several genes, including prohibitin, which was reversed by 1alpha-hydroxyvitamin D(5) (1alpha(OH)D(5)) treatment. The in silico screening for putative transcription factor binding sites identified two VDR/RXR binding sites in the 1kb promoter region of prohibitin. Other binding sites for EGR and GR which are also Vitamin D target genes were identified in this region, indicating that prohibitin is a potential target gene for Vitamin D. The combination of multiple binding sites also provides a basis for a possible dual regulation of prohibitin by Vitamin D. Prohibitin upregulation by 1alpha(OH)D(5) treatment at both transcription and translation level was observed in Vitamin D sensitive BT474 breast cancer cells, in which 1alpha(OH)D(5) significantly inhibited cell proliferation in normal culture condition. On the other hand, prohibitin down-regulation accompanied with Vitamin D mediated maintenance of proliferation of breast epithelial cells was observed under stressed condition. These results demonstrated that Vitamin D mediated antiproliferative activity in unstressed condition and growth maintaining activity under stressed condition involve differential expression of prohibitin.
Subject(s)
Breast/drug effects , Breast/metabolism , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Hormones/metabolism , Vitamin D/pharmacology , Base Sequence , Bromodeoxyuridine/metabolism , Cell Line , Cell Proliferation/drug effects , Dihydroxycholecalciferols/metabolism , Down-Regulation , Humans , Molecular Sequence Data , RNA, Small Interfering/genetics , Up-RegulationABSTRACT
The epidemic scourge of rickets in the 19th century was caused by vitamin D deficiency due to inadequate sun exposure and resulted in growth retardation, muscle weakness, skeletal deformities, hypocalcemia, tetany, and seizures. The encouragement of sensible sun exposure and the fortification of milk with vitamin D resulted in almost complete eradication of the disease. Vitamin D (where D represents D2 or D3) is biologically inert and metabolized in the liver to 25-hydroxyvitamin D [25(OH)D], the major circulating form of vitamin D that is used to determine vitamin D status. 25(OH)D is activated in the kidneys to 1,25-dihydroxyvitamin D [1,25(OH)2D], which regulates calcium, phosphorus, and bone metabolism. Vitamin D deficiency has again become an epidemic in children, and rickets has become a global health issue. In addition to vitamin D deficiency, calcium deficiency and acquired and inherited disorders of vitamin D, calcium, and phosphorus metabolism cause rickets. This review summarizes the role of vitamin D in the prevention of rickets and its importance in the overall health and welfare of infants and children.
Subject(s)
Rickets/epidemiology , Vitamin D Deficiency/epidemiology , Calcium/metabolism , Child , Child, Preschool , Dihydroxycholecalciferols/metabolism , Female , Humans , Hydroxycholecalciferols/metabolism , Male , Phosphorus/metabolism , Prevalence , Rickets/etiology , Rickets/genetics , Rickets/radiotherapy , Ultraviolet Rays , Vitamin D/radiation effects , Vitamin D Deficiency/radiotherapyABSTRACT
Immobilization induces significant and progressive bone loss, with an increase in urinary excretion and a decrease in intestinal absorption of calcium. These actions lead to negative calcium balance and the development of disuse osteoporosis. The aims of this study were to evaluate the molecular mechanisms of decreased intestinal calcium absorption and to determine the effect of dietary 1,25-dihydroxyvitamin D [1,25(OH)2D] and a high-calcium diet on bone loss due to immobilization. The immobilized rat model was developed in the Bollman cage III to induce systemic disuse osteoporosis in the animals. There was a significant decrease in lumbar bone mineral density (BMD) and intestinal calcium absorption in the immobilized group compared with the controls. Serum 25-hydroxyvitamin D concentration did not change, but 1,25(OH)2D concentration decreased significantly. The mRNA levels of renal 25-hydoxyvitamin D 24-hydroxylase (24OHase) increased, whereas those of renal 25-hydroxyvitamin D 1-alpha hydroxylase (1alpha-hydroxylase), duodenal transient receptor potential cation channel, subfamily V, member 6 (TRPV6), TRPV5, and calbindin-D9k were all decreased. A high-calcium diet did not prevent the reduction in lumbar BMD or affect the mRNA expression of proteins related to calcium transport. Dietary administration of 1,25(OH)2D increased the intestinal calcium absorption that had been downregulated by immobilization. TRPV6, TRPV5, and calbindin-D9k mRNA levels were also upregulated, resulting in prevention of the reduction in lumbar BMD. Therefore, it is concluded that dietary 1,25(OH)2D prevented decreases in intestinal calcium absorption and simultaneously prevented bone loss in immobilized rats. However, it remains unclear that calcium absorption and expression of calcium transport proteins are essential for the regulation of lumbar BMD.
Subject(s)
Calcium/metabolism , Dihydroxycholecalciferols/metabolism , Duodenum/metabolism , Immobilization/adverse effects , Intestinal Absorption , Animals , Calcium, Dietary , Humans , Rats , Rats, Wistar/metabolismABSTRACT
As part of our studies on the membrane-initiated actions of 1alpha,25-dihydroxyvitamin D(3) [1alpha,25(OH)(2)D(3)] and its localization in caveolae membrane fractions, we used a vitamin D receptor (VDR)-knockout (KO) mouse model to study the binding of [(3)H]-1alpha,25(OH)(2)D(3) in the presumed absence of the VDR. In this mouse model, known as the Tokyo strain, the second exon of the VDR gene, which encodes the first of the two zinc fingers responsible for DNA binding, was removed, and the resulting animals have been considered to be VDR-null mice. To our surprise, several tissues in these KO mice showed significant (5-50% of that seen in wild-type animals) specific binding of [(3)H]-1alpha,25(OH)(2)D(3) in nuclear and caveolae membrane fractions. The dissociation constants of this binding in samples from VDR-KO and wild-type mice were indistinguishable. RT-PCR analysis of intestinal mRNA from the VDR-KO animals revealed an mRNA that lacks exon 2 but contains exons 3-9 plus two 5'-untranslated exons. Western analysis of intestinal extracts from VDR-KO mice showed a protein of a size consistent with the use of Met52 as the translational start site. Transfection of a plasmid construct containing the sequence encoding the human analog of this truncated form of the receptor, VDR(52-C), into Cos-1 cells showed that this truncated form of the receptor retains full [(3)H]-1alpha,25(OH)(2)D(3) binding ability. This same construct was inactive in transactivation assays using the osteocalcin promoter in CV1 cells. Thus, we have determined that this widely used strain of the VDR-KO mouse can express a form of the VDR that can bind ligand but not activate gene transcription.
Subject(s)
Mice, Knockout/genetics , Mice, Knockout/metabolism , Receptors, Calcitriol/genetics , Receptors, Calcitriol/metabolism , 5' Untranslated Regions , Animals , Blotting, Western , COS Cells , Chlorocebus aethiops , Dihydroxycholecalciferols/metabolism , Exons , Humans , Intestinal Mucosa/metabolism , Mice , Mice, Inbred Strains , Peptide Fragments/metabolism , RNA/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
Recently, we demonstrated that some A-ring-modified vitamin D3 analogs had unique biological activity. Of these analogs, 2alpha-propoxy-1alpha,25(OH)2D3 (C3O1) and 2alpha-(3-hydroxypropoxy)-1alpha,25(OH)2D3 (O2C3) were examined for metabolism by CYP27A1 and CYP24A1. Surprisingly, CYP27A1 catalyzed the conversion from C3O1 to O2C3, which has 3 times more affinity for vitamin D receptor than C3O1. Thus, the conversion from C3O1 to O2C3 by CYP27A1 is considered to be a metabolic activation process. Five metabolites were detected in the metabolism of C3O1 and O2C3 by human CYP24A1 including both C-23 and C-24 oxidation pathways. On the other hand, three metabolites of the C-24 oxidation pathway were detected in their metabolism by rat CYP24A1, indicating a species-based difference in the CYP24A1-dependent metabolism of C3O1 and O2C3 between humans and rats. Kinetic analysis revealed that the Km and kcat values of human CYP24A1 for O2C3 are, respectively, approximately 16 times more and 3 times less than those for 1alpha,25(OH)2D3. Thus, the catalytic efficiency, kcat/Km, of human CYP24A1 for O2C3 is only 2% of 1alpha,25(OH)2D3. These results and a high calcium effect of C3O1 and O2C3 in animal experiments using rats suggest that C3O1 and O2C3 are promising for clinical treatment of osteoporosis.
Subject(s)
Cytochrome P-450 Enzyme System/metabolism , Dihydroxycholecalciferols/chemistry , Dihydroxycholecalciferols/metabolism , Steroid Hydroxylases/metabolism , Animals , Cattle , Cholestanetriol 26-Monooxygenase , Dose-Response Relationship, Drug , Humans , Isoenzymes/metabolism , Rats , Species Specificity , Vitamin D3 24-HydroxylaseABSTRACT
We have determined the crystal structures of the ligand binding domain (LBD) of the rat vitamin D receptor in ternary complexes with a synthetic LXXLL-containing peptide and the following four ligands: 1alpha,25-dihydroxyvitamin D(3); 2-methylene-19-nor-(20S)-1alpha,25-dihydroxyvitamin D(3) (2MD); 1alpha-hydroxy-2-methylene-19-nor-(20S)-bishomopregnacalciferol (2MbisP), and 2alpha-methyl-19-nor-1alpha,25-dihydroxyvitamin D(3) (2AM20R). The conformation of the LBD is identical in each complex. Binding of the 2-carbon-modified analogues does not change the positions of the amino acids in the ligand binding site and has no effect on the interactions in the coactivator binding pocket. The CD ring of the superpotent analogue, 2MD, is tilted within the binding site relative to the other ligands in this study and to (20S)-1alpha,25-dihydroxyvitamin D(3) [Tocchini-Valentini et al. (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 5491-5496]. The aliphatic side chain of 2MD follows a different path within the binding site; nevertheless, the 25-hydroxyl group at the end of the chain occupies the same position as that of the natural ligand, and the hydrogen bonds with histidines 301 and 393 are maintained. 2MbisP binds to the receptor despite the absence of the 25-hydroxyl group. A water molecule is observed between His 301 and His 393 in this structure, and it preserves the orientation of the histidines in the binding site. Although the alpha-chair conformer is highly favored in solution for the A ring of 2AM20R, the crystal structures demonstrate that this ring assumes the beta-chair conformation in all cases, and the 1alpha-hydroxyl group is equatorial. The peptide folds as a helix and is anchored through hydrogen bonds to a surface groove formed by helices 3, 4, and 12. Electrostatic and hydrophobic interactions between the peptide and the LBD stabilize the active receptor conformation. This stablization appears necessary for crystal growth.